OrbiMed
OrbiMed is a leading global healthcare investment firm that invests across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. Founded in 1989, OrbiMed seeks to invest globally in world-class healthcare companies to help drive innovation, address unmet medical needs, and improve patient outcomes. The firm provides tailored financing solutions and extensive global team resources to help build world-class healthcare companies. The firm focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. OrbiMed is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Hezliya, and other key global markets.
ABOUT ORBIMED
OrbiMed is a global healthcare investment firm that provides tailored financing solutions and global team resources to help build world-class healthcare companies.
OrbiMed's structure combines the focus of specialists dedicated to specific market sectors with the synergies of a broad investment team spanning both public equity and private markets around the world.
The firm has evolved into one of the largest dedicated healthcare investment firms worldwide, with approximately $18 billion in assets under management as of March 2024.
Notable investments included $400 million in debt financing to Caris Life Sciences Inc., $200 million in Series C funding to ADARx Pharmaceuticals Inc., and $200 million in Series B funding to Upstream Biosciences Inc.
ORBIMED STRATEGIES
OrbiMed's private equity strategy helps build portfolio companies into market leaders. The firm invests globally including North America, Asia, and Europe.
OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital, providing valuable financing solutions to owners of intellectual property.
OrbiMed manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. The firm invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide.